The selective overexpression of AXL in GI malignancies is associated with a poor clinical prognosis (9–11), proliferation (10, 12, 13), metastasis (14), immunosuppressive tumor microenvironment (3, 15, 16), and drug resistance (17, 18). This evidence concerns the gene AXL and neoplasm.